$NBIO ~ "Because EDV is found in a variety of cancers, our clinical trials involving PTB could have implications for a broad range of more common cancers, such as breast, colon and lung," noted Nascent CEO, Sean Carrick. "The current Phase 1 trial has been uniquely designed to ultimately treat a variety of brain cancers from gliomas and other primary brain tumors to brain metastases and leptomeningeal cancers arising from breast, lung and other solid tumors." https://finance.yahoo.com/news/nascent-biotech-opens-phase-1-120000666.html
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.